Efficacy and Safety of Suprachoroidal Triamcinolone Acetonide in Cases of Resistant Diabetic Macular Edema
Authors:
- Saud Ul Hassan MemonSMSaud Ul Hassan Memon
- Faisal NawazFNFaisal Nawaz
- Waleed AhmadWAWaleed Ahmad
- Maria SaleemMSMaria Saleem
Open Access
- 31 January 2023
- journal article
- research article
- Published by Lahore Medical and Dental College
- Vol. 17 (1) , 324-326
Abstract
Background and Aim: Patients with diabetes are at risk of losing their vision due to diabetic macular edema (DME). Symptoms of diabetic macular edema occur as fluid leaks from retinal vessels into the surrounding neural retina due to hypoglycemia-induced damage to the blood-retina barrier. The current study aimed to assess the safety and efficacy of suprachoroidal triamcinolone acetonide in resistant diabetic macular edema cases. Patients and Methods: This interventional case series was carried out on 32 diabetic macular edema cases in the Department of Ophthalmology, Hayatabad Medical Complex, Peshawar during the period from April 2019 to September 2019. All the patients above 16 years of age with Type-1 DM or Type-2 DM were enrolled in this study. Intraocular Pressure (IOP), Baseline Best Corrected Visual Acuity (BCVA), and Central Subfield Thickness (CST) were determined and recorded. Post-SCTA follow-up was done in one and three months. During follow-up, the measured clinical factors were noted and analyzed in SPSS version 26. Results: Of the total 32 diabetic macular edema cases, 15 (46.9%) were male and 17 (53.1%) were females. The overall mean age was 48.64 ± 8.72 years. The frequency of prior injections received were 6.2 with maximum 12 and minimum four. CST pre-injection mean value was 612.8 ± 198.3 um and CST post-injection mean value at one and three months was 308.6± 62.6 um and 302.72± 58.64 um respectively. Statistical significance was found in pre and post one-month CST injections. The BCVA pre-injection and post-injection mean value at one and three months was 0.8 ± 0.19 and 0.49 ± 0.29 and 0.39 ± 0.20 respectively. At the one and three months post injection, there was statistical significance for both pre and post injection CST. A mean IOP of 12.32 mmHg was recorded pre-injection. Previously, 14.82 mmHg and 14.48 mmHg of intraocular pressure were recorded respectively after one and three months of injection. Conclusion: The present study found that Triamcinolone Acetonide (TA) was administered for anatomical and functional improvement. OCT macular thickness can be improved and refractory diabetic macular edema can be reduced using SCT. Keywords: Resistant diabetic macular edema, Efficacy, Suprachoroidal TriamcinoloneKeywords
This publication has 25 references indexed in Scilit:
- Effect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME StudiesOphthalmology Retina, 2019
- Recent advances in slow and sustained drug release for retina drug deliveryExpert Opinion on Drug Delivery, 2019
- Outcome and Predictors for 2-Year Visual Acuity in Eyes with Diabetic Macular Edema Treated with RanibizumabJournal of Ocular Pharmacology and Therapeutics, 2019
- Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of the eye diseasesExpert Opinion on Drug Delivery, 2018
- Suprachoroidal Triamcinolone Acetonide for Diabetic Macular EdemaOphthalmology Retina, 2018
- Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite StudyOphthalmology Retina, 2018
- Choroidal Changes After Suprachoroidal Injection of Triamcinolone Acetonide in Eyes With Macular Edema Secondary to Retinal Vein OcclusionAmerican Journal of Ophthalmology, 2018
- Diabetic Macular Edema With and Without Subfoveal Neuroretinal Detachment: Two Different Morphologic and Functional EntitiesAmerican Journal of Ophthalmology, 2017
- Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial ResultsOphthalmology, 2015
- Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular EdemaOphthalmology, 2010